2024 EL PFDD Meeting on GBS, MMN, & Anti-Mag

Header image showing a person wearing a hat and holding a microphone. Header says "EL PFDD Virtual All-Day Meeting: Understanding the GBS, MMN, and Anti-Mag Patient Perspective, Thursday May 16th 2024"

To bring the patient perspective to the forefront of the drug development process, the GBS|CIDP Foundation is proud to announce that we are hosting an externally led Patient Focused Drug Development (EL PFDD) meeting on May 16th to elevate the patient voice of those with MMN, GBS, and Anti-Mag. With an audience consisting of regulators and researchers who are involved in the drug development process, this meeting will highlight the needs and preferences of the MMN, GBS, and Anti-Mag patient communities.

View the Agenda

Patient-Focused Drug Development (PFDD) is a systematic approach to help ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development and evaluation.

One of FDA’s missions is to protect and promote public health by evaluating the safety and effectiveness of new drugs, biologics, and devices. FDA does not develop drugs nor conduct clinical trials. FDA does, however, play a constructive role in guiding, helping, or evaluating at some stages of the pre-clinical, translational, and clinical development work.

Learn more about EL PFDD Meetings

GBS Panelists
MMN Panelists
Anti-Mag Panelists
Thank You to Our Sponsors!